Jeff Bradley, MD
@jeffbradleymd
Professor, University of Pennsylvania, #RadOnc, lung cancer and proton therapy specialist...Cardinals fan! Opinions are my own.
ID: 391658664
15-10-2011 22:24:50
315 Tweet
1,1K Followers
245 Following
Penn Radiation Oncology welcomes Dr. Jeffrey Bradley! Dr. Bradley specializes in thoracic malignancies with a focus on stereotactic body radiation therapy and proton beam therapy. Penn Medicine Jeff Bradley, MD For more info or to refer a patient: spr.ly/6013PwrXR
First ever trial of proton therapy and immunotherapy for reirradiation of recurrent NSCLC. Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer Jeff Bradley, MD Abigail T. Berman, MD, MSCE Nikhil Yegya-Raman redjournal.org/article/S0360-…
Anyone following #ProtonTherapy clinical trials knows how exciting this is! This trial has finally reached accrual due to the dedication of Zhongxing Liao, MD Jeff Bradley, MD, NRG Oncology and IROC staff, and the many participating institutions. Well done. Can’t wait to see the data!
So excited to complete accrual! Many thanks to Zhongxing Liao, MD, the enrolling investigators, and the patients for their tremendous efforts! Zhongxing Liao, MD NRG Oncology
Jeff Ryckman Teoman Yanmaz Stephen V Liu, MD Do you know if PAC2 had a cross over design? I’m sure Jeff Bradley, MD can confirm. Recall, Durva isn’t a standard of care for progression during or after CRT. Those who progressed (in either arm) very likely got something else.
Dr. Jeff Bradley, MD presents results from PACIFIC-2 at #ELCC24. Included pts with unresectable stage III NSCLC with randomization to chemoradiation with concurrent durvalumab/placebo followed by durvalumab/placebo consolidation. Note this was done before OS from PACIFIC known.
Drew Moghanaki 🐕 Gerry Hanna Jeff Bradley, MD Corinne Faivre-Finn 💙 Susan Harden Fiona McDonald Patrick Forde ESMO - Eur. Oncology Gerard Walls IASLC Jarushka Naidoo Sana Karam, MD, PhD Sorry can’t conclude anything at all from this trial, will comment in separate thread but this was unfortunately too flawed to learn much from.
Charu Aggarwal, MD, MPH, FASCO updates us on the potential of liquid biopsies in lung cancer at ELCC 2024! ESMO - Eur. Oncology IASLC Penn Medicine
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC @myesmo Jeff Bradley, MD Penn Medicine #ELCC24 #lcsm onclive.com/view/concurren…